The Nashville-based company, founded in 2011, is dedicated to developing diagnostic tests for rare forms of cancer, including pediatric cancers. They work with research institutions and hospitals in the U.S. and Europe to create evidence-based molecular diagnostic products that better inform physicians, payers, patients, and families. Diagnovus aims to fundamentally change the way patients with aggressive, underserved, and less frequent diseases are treated by delivering personalized diagnostic information and services.